n.chowdhury
TL2 Moderator · Setúbal
Contributes reviews on supplier material. Based in Setúbal.
Joined 9 May 2025 · last posted 3d
74 posts, newest first. Showing up to 150.
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #53 · Compounds › Repair & healing peptides · 25 Jul 2026 · 11 likes For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or…
-
Selection into a registry and what it does to the estimate — a second dataset Replied, post #28 · Evidence › Study critique · 23 Jul 2026 · 1 like Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #93 · Analytics › Impurities & related substances · 19 Jul 2026 · 7 likes post #92 answers the question as asked. The question underneath it is different. Dimer and higher-order multimers: two or more peptide molecules bonded together. They…
-
Sleep quality changes during weight loss Replied, post #21 · Wellbeing › Sleep · 17 Jul 2026 · 15 likes post #20 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #23 · Practice › Dosing & titration · 12 Jul 2026 · 10 likes How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used…
-
Conditions that change the calculus rather than forbidding it Replied, post #29 · Safety › Contraindications · 12 Jul 2026 · 1 like Worth separating two things that post #25 runs together. Disordered eating history: appetite suppression can trigger relapse in people with history of anorexia,…
-
What changed in 2026, by region — does this still hold? Replied, post #21 · Access › International · 8 Jul 2026 · 21 likes Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more…
-
[2026 update] Regional warehouse stock versus direct despatch Replied, post #125 · Sourcing › Logistics · 6 Jul 2026 · 5 likes Packaging integrity on arrival: if a parcel arrives with compromised packaging, that is evidence of a handling problem in transit. The contents may or may not be…
-
Pooling trials with different estimands Replied, post #45 · Evidence › Meta-analyses · 24 Jun 2026 · 24 likes This follows post #42 rather than contradicting it. When a meta-analysis is unhelpful: if the included studies are heterogeneous in population, intervention, or…
-
Insurance and replacement policies, compared Replied, post #25 · Sourcing › Logistics · 17 Jun 2026 · 21 likes Declaring contents accurately: declaring accurately reduces intervention risk. A declaration of "peptide research chemical, 5 grams" is better than "vitamin" or "other"…
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #36 · Analytics › HPLC & UHPLC · 15 Jun 2026 · 0 likes Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not the same number even on the same sample because…
-
[2026 update] Temperature indicator cards: worth asking for? Replied, post #4 · Sourcing › Logistics · 9 Jun 2026 · 2 likes This follows the opening post rather than contradicting it. Declaring contents accurately: declaring accurately reduces intervention risk. A declaration of "peptide…
-
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #53 · Outcomes › Progress reports · 1 Jun 2026 · 10 likes Seasonal patterns: some people report weight loss is slower in winter than summer. Body composition and activity changes might contribute. Noting the season is useful…
-
Bioimpedance and hydration: why the number moves Replied, post #49 · Outcomes › Body composition · 23 May 2026 · 9 likes On post #45 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
Alcohol: what is documented and what is folklore Replied, post #24 · Practice › Interactions · 23 May 2026 · 0 likes Alcohol: no absolute contraindication but it raises gastrointestinal irritation risk and this drug class already does that. The conservative position during titration…
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #73 · Compounds › Tirzepatide · 21 May 2026 · 11 likes Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that…
-
How much fluid is actually needed, and how you would know Replied, post #9 · Nutrition & Training › Hydration & electrolytes · 19 May 2026 · 0 likes Fluid intake: baseline needs increase with gastrointestinal effects and exercise. Thirst is not a reliable guide during appetite suppression. Drinking regularly (not…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #65 · Data & Tools › Datasets · 14 May 2026 · 8 likes Privacy: if contributing data, only share data you are comfortable making permanent and public. Once posted, data is persistent.
-
Rotating between abdomen, thigh and upper arm: absorption differences — one year on Replied, post #57 · Practice › Administration · 4 May 2026 · 8 likes Cold solution and stinging: warming the vial in your hands for a minute before injection reduces the stinging sensation substantially. This is the simplest thing to try…
-
Request: show the solution author in the topic list — what changed since Replied, post #55 · Meta › Feature requests · 3 May 2026 · 0 likes Picking up post #52: that is the part I would want checked first. Community support: if other people support your request, they can reply with "+1" or "I would use that…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #40 · Evidence › Journal club · 25 Apr 2026 · 27 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Hair shedding at month three: mechanism and time course — the long version Started this topic · Practice › Side effects · 17 Apr 2026 · 44 likes Hair shedding at month three: mechanism and time course — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting…
-
Sample handling between despatch and injection Replied, post #27 · Analytics › Method validation · 9 Apr 2026 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #5 · Practice › Reconstitution · 9 Apr 2026 · 32 likes Foaming during reconstitution: bubbles in the solution are usually just air incorporated during mixing. They usually resolve with gentle warming and time. Persistent…
-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #6 · Analytics › Home & field testing · 7 Apr 2026 · 28 likes What physical quantity does the device measure? A colorimetric or lateral-flow method typically responds to a class of chemistry rather than to a specific molecule. It…
-
Reused chromatograms across lots: how to spot it — what changed since Replied, post #26 · Analytics › COA interpretation · 24 Mar 2026 · 18 likes Water content (residual moisture) matters: lyophilised peptide is not dry. A few percent water is normal. The difference between a TFA salt and an acetate salt can be…
-
A parcel stationary at a customs facility for nine days — does this still hold? Replied, post #10 · Sourcing › Logistics · 18 Mar 2026 · 22 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #17 · Analytics › HPLC & UHPLC · 11 Mar 2026 · 4 likes Coming back to post #15, because the follow-up matters more than the original answer. Two things before anyone answers the substance. First, the context in the first…
-
Second pass at: Identical chromatograms across two different lots Replied, post #35 · Sourcing › Red flags · 1 Mar 2026 · 6 likes Inability to trace lots: if you ask "where was this synthesised, by whom, under what conditions" and cannot get a clear answer, that is a red flag. Traceability is not…
-
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still… Replied, post #4 · Compounds › Retatrutide · 1 Mar 2026 · 4 likes On the opening post — agreed on the reasoning, with one qualification. Retatrutide is investigational. Anything obtained outside a trial is by definition…
-
Journal club: LEADER as the historical anchor Replied, post #40 · Evidence › Journal club · 27 Feb 2026 · 1 like Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then…
-
Revisiting: Language barriers in accessing a prescription abroad Replied, post #133 · Access › International · 27 Feb 2026 · 23 likes This follows post #130 rather than contradicting it. Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by…
-
Preprint servers and what screening they do Replied, post #62 · Evidence › Preprints · 20 Feb 2026 · 8 likes Discussing preprints in this community: bring them in for early discussion, label them clearly as preprints, invite peer critique, and be prepared for the discussion to…
-
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #54 · Analytics › Impurities & related substances · 17 Feb 2026 · 24 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #7 · Analytics › Impurities & related substances · 8 Feb 2026 · 31 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Revisiting: Review: an evidence digest and the citation check that delayed it Replied, post #50 · Documentation › Doc review · 16 Jan 2026 · 0 likes New maintainer recruitment: if a page's maintainer is inactive and updates are needed, suggesting a new maintainer here can help transition responsibility.
-
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #8 · Practice › Storage & stability · 28 Dec 2025 · 2 likes Coming back to post #6, because the follow-up matters more than the original answer. Temperature excursions: if a vial sat at room temperature for a time, the question…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long… Replied, post #24 · Pharmacology › Receptor biology · 23 Dec 2025 · 0 likes Bias and desensitisation: receptors can be biased (preferentially activating some downstream pathways over others) and can desensitise over time (responding less to the…
-
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #12 · Practice › Side effects · 31 Oct 2025 · 20 likes Coming back to post #10, because the follow-up matters more than the original answer. Constipation: common, manageable, and frequently under-reported because it is not…
-
Where to report an adverse event officially, by region — a second dataset Replied, post #23 · Safety › Adverse events · 15 Oct 2025 · 19 likes How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.
-
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #105 · Compounds › Cagrilintide & amylin analogues · 6 Oct 2025 · 17 likes This follows post #102 rather than contradicting it. Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are…
-
Follow-up: The lowest dose that does anything: is that a real question? Replied, post #57 · Practice › Dosing & titration · 28 Sep 2025 · 3 likes The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long…
-
When a preprint is the best available evidence and we say so Replied, post #112 · Evidence › Preprints · 29 Aug 2025 · 0 likes Unrefereed work is not worthless. A great deal of it survives review substantially unchanged. It is also the case that the version appearing in a journal frequently has…
-
System suitability injections: if they failed, the run did not happen Replied, post #26 · Analytics › HPLC & UHPLC · 26 Aug 2025 · 0 likes This is why a purity figure without the underlying chromatogram is weaker evidence than it appears. It is also why two competent laboratories can report different…
-
Thyroid function tests during substantial weight change Replied, post #38 · Clinical › Bloodwork · 22 Aug 2025 · 6 likes Liver enzymes: elevation does not specify cause. ALT and AST can rise from many things. Bilirubin helps narrow down the cause. Multiple markers together are more…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #13 · Evidence › Journal club · 11 Aug 2025 · 0 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
-
When to stop reading forums, including this one Replied, post #9 · Wellbeing › Mental health · 26 Jul 2025 · 13 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Canadian access and provincial variation — one year on Replied, post #28 · Regional › North America · 25 Jul 2025 · 24 likes Regional variation in North America: access differs substantially by US state and Canadian province. Postcode is a major determinant of access.
-
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #20 · Sourcing › Vendor reports · 3 Jul 2025 · 8 likes What "verified" means on our pages: specific lots were independently measured on stated dates by named services and results were consistent with the supplier's…
-
Follow-up: Requesting a page: what makes a good request Replied, post #48 · Documentation › Wiki requests · 13 Jun 2025 · 7 likes Suggesting content for a page: if you know a maintained page is missing something important, post a suggestion with specific content you think should be added.
-
Follow-up: What other technical communities get right that we do not Replied, post #108 · Lounge › Off topic · 24 May 2025 · 0 likes Humour: light, relevant humour is welcome. Cruel humour targeting individuals or groups is not.
-
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #36 · Evidence › Trials · 23 May 2025 · 0 likes Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters.…
-
Hepatic steatosis: what the MASH trial evidence supports Replied, post #44 · Clinical › Comorbidities · 19 May 2025 · 6 likes Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct…
-
Pregnancy as an absolute contraindication Replied, post #19 · Safety › Contraindications · 17 May 2025 · 12 likes Medullary thyroid carcinoma (personal or family history) or multiple endocrine neoplasia type 2: absolute contraindication. The rodent preclinical signal is real enough…
-
Pages past their review date, listed — does this still hold? Replied, post #17 · Meta › Wiki maintenance · 8 May 2025 · 6 likes Maintainer handovers: if a page's maintainer is inactive and needs a new one, discussing that here can facilitate the transition.
-
Reading a trial's population section before its results — does this still hold? Replied, post #79 · Evidence › Trials · 8 May 2025 · 0 likes This follows post #76 rather than contradicting it. Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary…
-
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #111 · Compounds › Cagrilintide & amylin analogues · 7 May 2025 · 26 likes The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the…
-
Coverage for the indication versus for the drug Replied, post #37 · Access › Insurance & coverage · 21 Apr 2025 · 16 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Review cadence: how often is a page actually re-checked? Replied, post #15 · Documentation › Doc review · 10 Apr 2025 · 0 likes Evidence synthesis requests: if you think a page should summarise the state of evidence on a question, and you think the information exists but is scattered, suggest…
-
Reading a chromatogram someone posted without axes Replied, post #16 · Analytics › HPLC & UHPLC · 30 Mar 2025 · 1 like Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer run resolves more impurities and gives a higher purity…
-
Charge states for a 4 kDa peptide, worked through Replied, post #146 · Analytics › Mass spectrometry · 18 Mar 2025 · 7 likes Picking up post #143: that is the part I would want checked first. Resolution: "high resolution" commonly means
-
Revisiting: Aggregate verification data across the directory, with caveats Replied, post #24 · Sourcing › Independent verification · 5 Mar 2025 · 1 like post #23 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Pharmaceutical compounding rules, summarised from primary sources Replied, post #30 · Sourcing › Regulatory · 28 Feb 2025 · 0 likes This follows post #27 rather than contradicting it. Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It…
-
Coming back to: Official shortage notices and what they authorise Replied, post #39 · Access › Shortages · 24 Feb 2025 · 22 likes Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration…
-
A promotion I argued against, and why I lost Replied, post #87 · Documentation › Doc review · 6 Feb 2025 · 8 likes This follows post #84 rather than contradicting it. Revision disputes: if you disagree with an edit a maintainer made to a page, discuss it here. The goal is accuracy…
-
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #98 · Evidence › Journal club · 19 Jan 2025 · 17 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
-
Revisiting: What a well-designed human trial of a secretagogue would look like Replied, post #26 · Compounds › Secretagogues & GH axis · 11 Jan 2025 · 1 like IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates.…
-
Follow-up: Individual participant data versus aggregate data Replied, post #66 · Evidence › Meta-analyses · 10 Jan 2025 · 3 likes Picking up post #63: that is the part I would want checked first. Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If…
-
Request: a diff view for wiki revisions Replied, post #31 · Meta › Feature requests · 15 Dec 2024 · 30 likes post #30 is right about the mechanism and I think understates the practical bit. Duplicate requests: if several people request the same feature, the requests often get…
-
EMA product information as a primary source — does this still hold? Replied, post #105 · Regional › European Union · 17 Nov 2024 · 14 likes Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #9 · Clinical › Prescriber conversations · 26 Oct 2024 · 1 like Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit after a defined time, or other reasons? Knowing in advance is…
-
Type 2 diabetes and the largest part of the evidence base — does this still hold? Replied, post #16 · Clinical › Comorbidities · 3 Oct 2024 · 16 likes Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and…
-
Correlation in a self-tracked dataset: what it can support Replied, post #139 · Research Methods › Statistics · 25 Aug 2024 · 28 likes Absence of evidence and evidence of absence: if a study is small and finds no effect, that is absence of evidence, not evidence of absence. A larger study might find an…
-
Chronic kidney disease and the FLOW result Replied, post #14 · Clinical › Comorbidities · 14 Aug 2024 · 31 likes post #13 is right about the mechanism and I think understates the practical bit. Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed…